Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PIEX 3 is a plant-identical cannabis raw extract (Rohextrakt) developed by Becanex. It is standardized to contain 62% cannabidiol (CBD) and less than 5% tetrahydrocannabinol (THC), derived consistently from the God Bud cannabis strain (an Indica-dominant hybrid). The extraction process preserves the natural cannabinoid and terpene fingerprint of the source flower to leverage the entourage effect. PIEX 3 is designed for pharmacy compounding into various medicinal forms, including inhalation solutions for vaporization, oral oils, capsules, suppositories, and topical preparations, and is available for medical prescription in Germany.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PIEX 3.